

Ministry of Health, Welfare and Sport

> Return address P.O.-box 20350 2500 EJ The Hague, The Netherlands

The Ambassadors of the EU Member States in the Netherlands

International Affairs**Address**

Parnassusplein 5
2511 VX The Hague
T +31 070 3407911
F +31 070 3407934

Information

(10)(2e)

M (10)(2e)

(10)(2e)@minvws.nl

Our reference

1708029-207151-1Z

Your reference**Enclosure(s)****Date**

Subject The Inclusive Vaccine Alliance (TIVA)

Dear Ambassador,

You will probably have heard about the initiative of Germany, France, Italy and the Netherlands to join forces in the "Inclusive Vaccine Alliance". The aim of this cooperation is to make a good and safe COVID-19 vaccine available to the Member States of the European Union and their citizens as quickly as possible.

Since the development of a vaccine is expensive and complex and as we are not sure which of the ongoing initiatives will lead to a working vaccine, we believe that collaboration and risk sharing are of great importance.

However, it is also important to act quickly, since many countries worldwide are also busy buying themselves into different schemes. Germany, France, Italy and the Netherlands, as leading countries in Europe in the field of vaccine development and production, have therefore joined forces. Not just for ourselves, but for all member states of the European Union, so the entire European population can benefit from an effective and safe vaccine against COVID-19. In addition, the alliance strives to make some of the vaccines available to lower-income countries, including Africa.

We are currently discussing how to work with the European Commission on future negotiations. Further details will follow in the coming days. The primary goal is to reach so-called Advanced Purchase Agreements (APA). These agreements allow participating countries to purchase vaccines for a pre-agreed price. In the event of scarcity, distribution will take place in proportion to the population of the Member States.

Last week, the Alliance signed a first contract with pharmaceutical company AstraZeneca (AZ). This agreement ensures that if AZ's efforts lead to a safe and effective vaccine, 300 to 400 million vaccines will become available to the participating EU Member States at cost price by the end of 2020. All EU Member states can opt-in, under the same legal conditions as the initiators.

All correspondence addressed to the postal address quoting date and reference of this letter.

We realize that some Member States have questions and even doubts about this process. The purpose of this letter is to give you more information about the initiative. If you should have any further questions, or if parties in your country wish to get in touch with The Inclusive Vaccine Alliance, please contact (10)(2e) (10)(2e) of the International Affairs Department of VWS (+ 31- (10)(2e) / (10)(2e) @minvws.nl).

International Affairs
Team B

Our reference
1708029-207151-1Z

Yours sincerely,

Let op: vul A.U.B. de ondertekengegevens NIET handmatig in. Dit tekstvak mag ALLEEN worden verwijderd op het moment dat het stuk in 'Printen en Verzenden' zit en de ondertekening volledig is. De ondertekengegevens 'naam ondertekenaar' en 'functie ondertekenaar' worden automatisch door Marjolcin ingevuld, vlak voordat het stuk ter ondertekening wordt aangeboden.